BioFire, Focus, IQuum Share $23.1M to Develop Platform, Assays for Biological Warfare Agent Detection | GenomeWeb

NEW YORK (GenomeWeb News) – The Department of Defense has awarded more than $23 million to three firms for the development of a platform and assays to detect biological warfare agents, the agency announced last week.

BioFire Diagnostics, Focus Diagnostics, and IQuum will share the $23.1 million cost-plus-fixed-fee multiple award task order contract being awarded through the US Army to develop a US Food and Drug Administration-cleared diagnostic platform and related FDA-cleared biological warfare agent in vitro diagnostic assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.